Clinical Trials

Sponsor: Aravive, Inc.

Sponsor Study ID: AVB500-RCC-003

Study Title: A PHASE 1B/2 STUDY OF AVB S6 500 IN COMBINATION WITH CABOZANTINIB, AVB S6 500 IN COMBINATION WITH CABOZANTINIB AND NIVOLUMAB, AND AVB S6 500 MONOTHERAPY IN PATIENTS WITH ADVANCED OR METASTATIC CLEAR CELL RENAL CELL CARCINOMA

NCT Number: NCT04300140

Phase: I/II

Protocol Type: Treatment

Age Group: Adult

Disease Sites: Kidney

Study Objectives: This is a Phase 1b/2 study of AVB-S6-500 designed to evaluate the safety and efficacy of AVB-S6-500 in combination with cabozantinib in subjects with advanced clear cell renal cell carcinoma (ccRCC) that have received front-line treatment. The phase 1b portion of the study is open label and patients will receive AVB-S6-500+Cabozantinib in 3+3 dose escalation. The Phase 2 portion of the study is randomized, 2-arm, open-label study to compare efficacy and tolerability of AVB-S6-500+cabozantinib versus cabozantinib alone.

For more information about the trial above please contact the study team:

Principal Investigator, Theodore Gourdin, at gourdith@musc.edu.
Study Coordinator, Carly Fecio, at fecio@musc.edu.

Trial opened at the following institutions: Medical University of South Carolina

Study Documents
(MUSC NetID required for document access)